The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers

International Journal of Cancer. Journal International Du Cancer
Umberto MiglioAnna Sapino

Abstract

Demethylation of the long interspersed nuclear element (LINE-1; L1) antisense promoter can result in transcription of neighboring sequences as for the L1-MET transcript produced by the L1 placed in the second intron of MET. To define the role of L1-MET, we investigated the sequence and the transcription of L1-MET in vitro models and heterogeneous breast cancers, previously reported to show other L1-derived transcripts. L1-MET expressing cell lines were initially identified in silico and investigated for L1-MET promoter methylation, cDNA sequence and cell fraction mRNA. The transcriptional level of L1-MET and MET were then evaluated in breast specimens, including 9 cancer cell lines, 41 carcinomas of different subtypes, and 11 normal tissues. In addition to a L1-MET transcript ending at MET exon 21, six novel L1-MET splice variants were identified. Normal breast tissues were negative for the L1-MET expression, whereas the triple-negative breast cancer (TNBC) and the high-grade carcinomas were enriched with the L1-MET mRNA (p = 0.005 and p = 0.018, respectively). In cancer cells and tissues the L1-MET expression was associated with its promoter hypomethylation (ρ = -0.8 and -0.9, respectively). No correlation was found between L1...Continue Reading

References

Dec 1, 1990·Molecular and Cellular Biology·G D Swergold
Sep 30, 1991·International Journal of Cancer. Journal International Du Cancer·M PratP M Comoglio
Aug 1, 1997·Trends in Genetics : TIG·J A YoderT H Bestor
Sep 30, 1999·American Journal of Respiratory Cell and Molecular Biology·T NagahoriK Yamamoto
Mar 10, 2001·Nature·E S LanderUNKNOWN International Human Genome Sequencing Consortium
Apr 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Brook BrouhaHaig H Kazazian
May 5, 2004·Proceedings of the National Academy of Sciences of the United States of America·Gangning LiangPeter A Jones
Aug 1, 2006·Journal of Biomedicine & Biotechnology·Kert MätlikMart Speek
Aug 28, 2009·The Journal of Biological Chemistry·Dongsheng YanLili Tu
Dec 1, 2011·Nature Methods·Xin ZhouTing Wang
Sep 8, 2012·Nature·UNKNOWN ENCODE Project Consortium
Oct 12, 2012·Breast Cancer Research and Treatment·Long ChenDanny Rangasamy
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Mar 13, 2014·The American Journal of Pathology·Nemanja RodićKathleen H Burns
Oct 12, 2014·Current Opinion in Cell Biology·Carla Boccaccio, Paolo M Comoglio
May 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CoatesUNKNOWN Panel Members
May 30, 2015·Retrovirology·Luisa Robbez-Masson, Helen M Rowe
Oct 21, 2015·Biopreservation and Biobanking·Latarsha J CarithersUNKNOWN GTEx Consortium
Jun 16, 2016·BMC Genomics·Steven W CriscioneNemanja Rodić

❮ Previous
Next ❯

Citations

Jan 10, 2020·Cancer Genetics·Andrea Cervantes-AyalcMiguel Ángel Velázquez-Flores
May 1, 2021·International Journal of Molecular Sciences·Vladimir NosiRaffaele A Calogero
Jun 3, 2021·International Journal of Molecular Sciences·Jiayue-Clara JiangKyle R Upton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.